To see the other types of publications on this topic, follow the link: Chronic Hepatitis C (CHC).

Journal articles on the topic 'Chronic Hepatitis C (CHC)'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chronic Hepatitis C (CHC).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tkachenko, L. I., and V. V. Maleev. "Insulin resistance and chronic hepatitis C." Terapevticheskii arkhiv 88, no. 11 (2016): 29–36. http://dx.doi.org/10.17116/terarkh2016881129-36.

Full text
Abstract:
Aim. To estimate the spread of insulin resistance (IR) in patients with chronic hepatitis C (CHC) and to define the role of IR in the development of hepatic steatosis (HS) and in the progression of liver fibrosis (LF), as well as the impact of IR on the results of antiviral therapy (AVT). Subjects and methods. A total of 211 patients with CHC were examined. A comparison group consisted of 75 patients with chronic hepatitis B (CHB). The patients were divided according to the presence and absence of IR and type 2 diabetes mellitus (DM). IR was analyzed in patients with CHC with a body mass index (BMI) of
APA, Harvard, Vancouver, ISO, and other styles
2

Abdikerimova, M. M. "PREGNANCY AND CHILDBIRTH COURSE PECUARITIES IN WOMEN SUFFERING FROM CHRONIC VIRAL HEPATITIS." Hepatology and Gastroenterology 8, no. 1 (2024): 31–35. http://dx.doi.org/10.25298/2616-5546-2024-8-1-31-35.

Full text
Abstract:
Background. Chronic viral hepatitis (CVH) B and C are considered socially significant infections. More than 290 million people worldwide live with chronic hepatitis B (CHB) and more than 58 million have been infected with hepatitis C virus (HCV). Every year, about 1.5 million people become newly infected. In recent years, chronic hepatitis has occupied one of the leading places in the structure of extragenital pathology in pregnant women. Objective. To evaluate the characteristics of pregnancy and childbirth course in women with CHB, CHC and CHB+СHC. Material and methods. The paper presents the results of a retrospective analysis of 141 individual records of pregnant women with CHB, CHC and CHB+СHC and their birth histories. The average age of pregnant women was 25.1±3.72 years. Results. CHB, CHC and CHB+СHC negatively affect the course of pregnancy: the threat of miscarriage and the frequency of gestosis increase, chronic fetoplacental insufficiency and polyhydramnios are more often detected, premature birth occurs as well. Childbirth in pregnant women with chronic hepatitis is accompanied by the development of complications: hypotonic uterine contractions, premature rupture of membranes. Chronic HCV-infection causes more serious metabolic changes than HBV, which significantly complicate the course of pregnancy and childbirth. Conclusions. CHB, CHC and CHB+СHC negatively affect the course of pregnancy and childbirth.
APA, Harvard, Vancouver, ISO, and other styles
3

Loosen, Sven H., Alexander Killer, Hans Henrich Bock, Tom Luedde, Christoph Roderburg, and Karel Kostev. "Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study." Journal of Clinical Medicine 13, no. 20 (2024): 6152. http://dx.doi.org/10.3390/jcm13206152.

Full text
Abstract:
Background: Osteoporosis and bone fractures affect health and quality of life. Since bone disease is multifactorial, identifying risk factors is key in prevention. There are multiple reports on how viral hepatitis, especially chronic hepatitis B (CHB) and chronic hepatitis C (CHC), are affecting bone disease, but results vary. Here, we analyzed the potential association between CHB/CHC and osteoporosis or bone fractures in a large outpatient cohort in Germany. Methods: We included 3136 outpatients with CHB and 15,608 matched non-hepatitis individuals as well as 2867 outpatients with CHC and 14,335 matched non-hepatitis individuals from the Disease Analyzer Database between 2005 and 2022. The main outcome was the 5-year cumulative incidence of osteoporosis and bone fractures as a function of either CHB or CHC. Results: Within 5 years of the index date, 2.9% vs. 1.6% of patients with and without CHB were diagnosed with osteoporosis (p = 0.001) and 1.0% vs. 0.4% were diagnosed with bone fractures (p < 0.001). Moreover, 3.3% of CHC patients and 2.2% of individuals without hepatitis C were diagnosed with osteoporosis (p = 0.002). In Cox regression analyses, CHB was significantly associated with an increased risk for osteoporosis (HR: 1.76) and fractures (HR:2.43) and CHC with osteoporosis (HR: 1.54). For both CHB and CHC, the association with osteoporosis was restricted to the female subgroup. Conclusions: CHB and CHC are associated with osteoporosis in women. CHB in male patients is associated with a higher risk of fractures. More research is needed to understand the underlying pathophysiological mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
4

Malghani, Waseem Sarwar, Farooq Mohyud Din Chaudhary, Muhammad Ali Wadhak, Asma Tameez Ud Din, Anum Khakwani, and Asim Tameez Ud Din. "CHRONIC HEPATITIS C." Professional Medical Journal 25, no. 06 (2018): 860–64. http://dx.doi.org/10.29309/tpmj/2018.25.06.271.

Full text
Abstract:
Background: Pegylated interferon (PEG-IFN) plus ribavirin combination was themain treatment for chronic hepatitis C (CHC) patients in Pakistan till 2016. An important sideeffect of this combination was thyroid dysfunction (TD). Objectives: To evaluate thyroid functionabnormalities in Chronic Hepatitis C patients treated with PEG-IFN and ribavirin. Study Design:Descriptive study. Setting: Outpatient Department of Gastroenterology and Hepatology,Nishtar Hospital Multan. Period: January to September 2016. Methods: Using non-probabilityconsecutive sampling. There were 337 CHC patients enrolled in the study who fulfilled theinclusion criteria. Patients were given PEG-IFN plus ribavirin combination therapy and at 12weeks their serum Thyroid Stimulating Hormone (TSH) levels were measured to identify any TD.Data was entered and analyzed by computer program SPSS-17. Results: Of these 337 cases,211 (62.6%) were male patients while 126 (37.4%) were female patients. Mean age of our caseswas noted to be 30.92 ± 5.84 years. Mean disease duration was 16.19 ± 6.42 months. In ourstudy 98 patients (29.1%) had genotype 2 while 239 (70.9%) had genotype 3. TD was seenin 28 (8.3%) patients, 70% of whom were females. Equal number of cases of Hypothyroidismand hyperthyroidism were seen (14 each). Hypothyroidism was significantly associated withrelatively older age group patients and genotype 3 (p value <0.05). A statistically significantassociation (p<0.05) was found between hyperthyroidism and genotype 3, female gender andyounger patients. Conclusion: PEG-IFN plus ribavirin combination therapy induces TD amongpatients with CHC with equal incidence of hypothyroidism and hyperthyroidism.
APA, Harvard, Vancouver, ISO, and other styles
5

Abdikerimova, M., A. Kanatbekova, and M. Abdikerimov. "Concomitant Diseases in Pregnant Women Suffering with Chronic Viral Hepatitis B and C." Bulletin of Science and Practice 10, no. 8 (2024): 247–53. http://dx.doi.org/10.33619/2414-2948/105/28.

Full text
Abstract:
The work identified concomitant diseases in 120 pregnant women suffering from chronic viral hepatitis B and C (CHB and CHC), aged 19 to 30 years. In the structure of extragenital pathology, the largest percentage belongs to diseases of the gastrointestinal tract, which was detected in 71.0% of 69 patients with CHB, in 76.5% of 51 pregnant women with CHC and in 42.1% of 57 relatively healthy pregnant women. Among the nosological forms were mainly chronic gastritis, chronic gastroduodenitis, biliary dyskinesia and chronic pancreatitis. Chronic viral hepatitis in pregnant women determines a high incidence of gastrointestinal tract damage due to biliary dyskinesia, apparently associated with viral liver damage. Urogenital infections among pregnant women are significantly more common in patients with CHB (59.4%) and CHC (80.3%) (p <0.05) than in those without liver pathology (21.5%). Among the urogenital infections, the most common was a combination of chlamydia and candidiasis, and less frequently, trichomonas infection, and only one patient was diagnosed with syphilis. Chronic viral hepatitis is a factor contributing to the development of urogenital infection in pregnant women.
APA, Harvard, Vancouver, ISO, and other styles
6

Sobhy, Ali, Mohammed Fakhry M., Haitham A Azeem, Ahmed M. Ashmawy, and Hamed Omar Khalifa. "Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus." Journal of Investigative Medicine 67, no. 3 (2018): 681–85. http://dx.doi.org/10.1136/jim-2018-000840.

Full text
Abstract:
Several studies were performed to evaluate the degree of liver fibrosis by non-invasive markers. We aimed to assess the diagnostic value of both biglycan (BGN) and osteopontin (OPN) as non-invasive markers of hepatic fibrosis in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). This study was performed on 100 patients with CHB virus, 100 patients with CHC virus and 100 normal controls. All participants were subjected to the following laboratory tests: hemoglobin, platelet, alanine aminotransferase, aspartate aminotransferase, albumin, international normalized ratio, HBs Ag, hepatitis C virus (HCV) antibody, hepatitis B virus DNA, HCV RNA, liver biopsy, BGN and OPN. We found that BGN level was significantly increased in the CHB group compared with the controls (p<0.001), but the level was not different between the CHC group and the controls (p<0.96). OPN was increased in both the CHB and CHC groups compared with the controls (p<0.001). Positive correlation was found between fibrosis stages and BGN level of the CHB group (r=0.64; p<0.001) and between fibrosis stages and OPN level of the CHB (r=0.63; p<0.001) and CHC (r=0.59; p<0.03) groups. The area under the curve (AUC), sensitivity and specificity of BGN were 1.0, 100% and 100% in predicting fibrosis in patients with CHB, and 0.50, 26% and 78% in predicting fibrosis in patients with CHC. OPN had an AUC of 0.997, sensitivity of 96% and specificity of 100% in predicting fibrosis in patients with CHB, and 0.974, 96.5% and 100% in predicting fibrosis in patients with CHC. In conclusion, BGN and OPN could be considered non-invasive markers for liver fibrosis assessment.
APA, Harvard, Vancouver, ISO, and other styles
7

Abdikerimova, M., A. Kanatbekova, M. Abdikerimov, and S. Zholdoshev. "Indicators of Immunological Status in Pregnant Women with Chronic Viral Hepatitis B and C." Bulletin of Science and Practice 10, no. 5 (2024): 342–49. http://dx.doi.org/10.33619/2414-2948/102/43.

Full text
Abstract:
The work presents the results of a study of immunological indicators of cellular and humoral immunity in 45 pregnant women with chronic viral hepatitis B and C. Immunological parameters in pregnant women with CHB and CHC were characterized by suppression of the cellular component of immunity, which is manifested by a decrease in the number of total T-lymphocytes (CD3+), T-helpers (CD4+) and T-suppressors (CD8+), as well as natural killer cells (CD16), which is associated with the mechanism of maintaining pregnancy. Changes in humoral immunity are characterized by a moderate increase in the level of IgG and CEC; in case of CHC, relapse of the disease was also accompanied by an increase in class M immunoglobulins. Chronic viral hepatitis B and C in pregnant women leads to secondary immunodeficiency and an increase in the level of viral replication. A direct correlation has been revealed between indicators of the cellular immune response in CHB and CHC with the level of viral load, which must be taken into account when managing pregnancy.
APA, Harvard, Vancouver, ISO, and other styles
8

Volynets, G. V., and A. I. Khavkin. "Chronic viral hepatitis and inflammatory bowel disease." Voprosy dietologii 11, no. 2 (2021): 29–34. http://dx.doi.org/10.20953/2224-5448-2021-2-29-34.

Full text
Abstract:
The article presents the results of a literature review devoted to the study of the problems of the combined course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), and chronic viral hepatitis (CVH) – chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The frequency of occurrence of CHB and CHC in IBD in different countries is presented, which ranges from 1 to 9%. The clinical course of these combined diseases, the possibility of reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) during immunosuppressive therapy are described. Recommendations on the specifics of examination and management of patients with combined pathology of IBD and CVH are presented. Conclusion. The combined pathology of IBD and CVH is a significant public health problem around the world that requires further large-scale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should be individualized. Key words: inflammatory bowel disease, chronic hepatitis B, chronic hepatitis C, immunosuppressive therapy
APA, Harvard, Vancouver, ISO, and other styles
9

Volynets, G. V. "CHRONIC VIRAL HEPATITIS AND INFLAMMATORY BOWEL DISEASE." Hepatology and Gastroenterology 5, no. 2 (2021): 111–17. http://dx.doi.org/10.25298/2616-5546-2021-5-2-111-117.

Full text
Abstract:
The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%. The clinical course of these concurrent diseases, the possibility of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation during immunosuppressive therapy are described. Recommendations on the peculiarities of examination and management of patients with concurrent pathology of IBD and CVH are presented. The combined pathology of IBD and CVH is a significant public health problem worldwide that requires further largescale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should occur on an individual basis.
APA, Harvard, Vancouver, ISO, and other styles
10

Yakovlev, A. A., A. Ya Komarova, V. B. Musatov, et al. "Current trends of the changes of the etiological structure and clinical and laboratory characteristics of hepatocellular carcinoma." Epidemiology and Infectious Diseases 18, no. 6 (2013): 21–27. http://dx.doi.org/10.17816/eid40771.

Full text
Abstract:
The etiological structure of chronic viral hepatitides with the outcome in hepatocellular carcinoma (HCC) was studied among deceased patients for the periods of 1986-1998 and 2002-2012 in total and in comparison. HCC developed as the outcome of CHB in 45.0% of patients, CHC - in 20.7 % , CHB+C - 18,6%, CVHN- in 12.9%, CHB + D - 1.4%, CHB+C+D - also in 1.4% of patients. When comparing the data for 1986-1998 (13 years), and 2002-2012 (11 years) there was noticed an increase in the number of deaths from HCC (2-fold), there was significantly increased the incidence of HCC, associated with CHC (from 2.0% to 30.8 %), nonverified chronic hepatitis as a cause of HCC occurred 6.5 times less often (28.6 % - 4.4%), the number of cases of HCC, caused by CHB, became lower (49.0 % - 42.9 %), CHB+C - almost unchanged (20.4% - 17.6 % ). A presumptive middle time of the development of HCC since infection with hepatitis viruses is 27,6 ± 9,8 years. In assessing the cofactors ofprogression of HCC there was found that alcohol abuse occurred in 38.5 % ofpatients, diabetes - in 18,7%, HIV- infection -in 3.3%.
APA, Harvard, Vancouver, ISO, and other styles
11

Baramzina, S. V. "Chronic hepatitis B and C as stigma: Is the problem relevant for Russian society?" Terapevticheskii arkhiv 91, no. 11 (2019): 4–9. http://dx.doi.org/10.26442/00403660.2019.11.000403.

Full text
Abstract:
Chronic hepatitis B and C (CHB and CHC) are a serious medical and social problem of the world community. Aim: to study the problem of stigmatization and attitudes to patients with CHB and CHC among adolescents and adults. Materials and methods. An anonymous survey was conducted in 120 residents of the Kirov region. Of these, 94 adults (aged 18 to 76 years; average age 39.3±11.5 years) of different specialties except medical (group 1) and 26 adolescents aged 16-17 years (average age 16.5±0.5 years), high school students (group 2). The original questionnaire included 16 questions divided into 3 blocks. Block 1 contained questions about the socio - demographic status of the Respondent, block 2 and block 3 included questions on the epidemiology of HCV and HBV infection and on the treatment of patients with CHC and CHB respectively. Results. In the course of work the majority of respondents (50-65.4%) from both groups revealed a negative attitude towards patients with CHB and CHC (to a lesser extent pronounced against close relatives and friends of CHC patients), manifested by a desire to exclude casual contact and refusal to live in the same room with the patient CHB/CHC, no desire of sharing your child/brother in the same kindergarten group patients with CHB/CHC child. Fear of Contracting HBV/HCV infection has been linked to poor knowledge of the factors and pathways of transmission of these diseases. In a few cases, adolescents and adults showed an extreme degree of destructive attitude, which was expressed in the adoption of discriminatory measures against this category of patients - dismissal from work and expulsion from school/University. Conclusion. The results indicate that there is a problem of stigmatization of patients with CHB and CHC in society, both in children and adults, which requires systematic work on health education.
APA, Harvard, Vancouver, ISO, and other styles
12

Baramzina, S. V. "Assessment of awareness about the epidemiology, outcomes, and therapy of chronic hepatitis B and C in adolescents and adults." Terapevticheskii arkhiv 88, no. 11 (2016): 37–42. http://dx.doi.org/10.17116/terarkh2016881137-42.

Full text
Abstract:
Aim. To estimate the level of knowledge in adults and adolescents about the issues related to viral hepatitis B and C: the transmission modes, course, and outcomes of acute and chronic hepatitis B (CHB) and C (CHC), as well as about current measures for their prevention and treatment. Subjects and methods. A total of 850 dwellers of Kirov and the Kirov Region were anomalously surveyed using an original questionnaire in 2013- 2015. The questionnaire included 24 questions on the etiology, epidemiology, outcomes, prevention, and treatment of CHB and CHC and on the sources of information. Persons younger than 16 years, people who had medical specialties, and those who were studying at a higher or secondary medical institution were excluded from the study. Results. Low levels of knowledge about the epidemiology, course, and outcomes of CHB and CHC were found in the adolescents and adults. 76.4% and 73.9% of the respondents had no clear idea as to the modes and factors of transmission of hepatitis B and C, respectively. A lack of knowledge of the issues associated with poor CHB and CHC outcomes (cirrhosis and hepatocellular carcinoma) was revealed in 84.8 and 76.2%, respectively. 81.8% of the respondents were well aware of the existence and necessity of vaccination against hepatitis B. 40.8% of the survey participants misbelieved that hepatitis C vaccine had been designed and used. Conclusion. A significant portion of the adult population is poorly aware of the problem of viral hepatitis B and C and needs to continue health education for the development and strengthening of a negative attitude towards narcotics and promiscuity; to combat false ideas about viral hepatitis; and enhance motivation for the specific and nonspecific prevention of hepatitis B and C.
APA, Harvard, Vancouver, ISO, and other styles
13

Barbu, Ecaterina Constanța, Cristina Emilia Chiţu-Tișu, Mihai Lazăr, et al. "Body Composition Changes in Patients with Chronic Hepatitis C." Journal of Gastrointestinal and Liver Diseases 25, no. 3 (2016): 323–29. http://dx.doi.org/10.15403/jgld.2014.1121.253.hpc.

Full text
Abstract:
Aims: We aimed to quantify global and regional body composition changes in chronic hepatitis C (CHC) patients, compare them to healthy controls and identify possible association between body composition changes and CHC. To our knowledge, this study is the first one comparing CHC patients to controls with regard to soft tissue body composition changes.
 Methods: We assessed 60 CHC patients and 60 healthy controls by Dual Energy X-Ray Absorptiometry. Soft tissue and bone body composition parameters were compared between the groups (using the Mann-Whitney test). These parameters were correlated (using Spearman’s rank correlation coefficient – rho) with independent variables (age, gender, body mass index – BMI, cigarette smoking, time since CHC diagnosis, viral load, fibrosis grade, type of treatment, time of treatment) for the entire CHC group and also for subgroups according to gender.
 Results: Total fat mass, trunk fat mass and percent body fat were lower in CHC patients as compared to controls. Several risk factors were associated with the reduced fat mass: low BMI, cigarette smoking and peginterferon alpha 2a plus ribavirin treatment. Peginterferon alpha 2a and ribavirin treatment negatively correlated with lean body parameters, especially in CHC males group. Bone mineral density (BMD) was lower as compared to controls and was correlated with low BMI, cigarette smoking and peginterferon alpha 2a and ribavirin treatment.
 Conclusions: Patients with CHC have an acquired type of lipodystrophy (particularly in the trunk region), and also a reduced BMD as compared with controls. A low BMI, cigarette smoking and peginterferon alpha 2a and ribavirin therapy were associatd with a low fat mass and low BMD.
 Abbreviations: BMD: bone mineral density; BMI: body mass index; CHC: chronic hepatitis C; DXA: Dual Energy X ray Absorptiometry; FM: fat mass; FMR: fat mass ratio; HCADS: hepatitis C associated dysmetabolic syndrome; HCV: hepatitis C virus; HO: hepatic osteodystrophy; LS: lumbar spine; LM: lean mass; PBF: percent body fat.
APA, Harvard, Vancouver, ISO, and other styles
14

Pár, Alajos. "Diagnosis and Management of Chronic Hepatitis C." Canadian Journal of Gastroenterology 14, suppl b (2000): 83B—88B. http://dx.doi.org/10.1155/2000/707182.

Full text
Abstract:
This mini-review is devoted to the main questions of diagnosis, treatment and prevention of chronic hepatitis C (CHC). Diagnosis of CHC is based on virological, biochemical and histological findings. The etiology of CHC should be proven by the presence of antibody to hepatitis C virus (anti-HCV) and detection of viral nucleic acid (HCV RNA), using qualitative and quantitative polymerase chain reaction or branched chainDNAtechniques. Serum aminotransferase levels can reflect the biochemical activity of liver disease, while biopsy is very important in the grading and staging of the pathological process. The generally accepted treatment ofCHCis interferon (IFN); however, recently, the combination of IFN with the oral nucleoside analogue ribavirin has become the therapy of choice, not only for relapsers but also for naive patients. Prevention of hepatitis C by vaccination is not yet available. Screening blood donors and members of high risk groups, as well as ensuring good public health measures, are imperative to inhibit the spread of HCV.
APA, Harvard, Vancouver, ISO, and other styles
15

Tekin, Süda, Şua Sümer, Neşe Demirtürk, and Bilgehan Aygen. "Chronic Hepatitis C in the Pandemic." Klimik Dergisi/Klimik Journal 34, no. 1 (2021): 13–17. http://dx.doi.org/10.36519/kd.2021.03.

Full text
Abstract:
Corona virus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, affected all the world and has been a major cause for significant morbidity and mortality. COVID-19 represents with pulmonary manifestations, but in more than half of the cases, other organs, especially hepatic involvement, are observed. Chronic hepatitis C (CHC) is an important public health problem worldwide. Sustained virological response (SVR) can be achieved and HCV-related mortality and morbidity can be prevented with direct-acting antiviral agents (DAAs), which have been used in recent years. However, if CHC is not diagnosed, it can cause cirrhosis and liver cancer. Since the diagnosis and treatment of these patients require follow-up, they are among the most affected chronic diseases during the pandemic. It does not seem possible to predict when the COVID-19 outbreak will end. Diagnosis and treatment need of CHC patients should be met in special areas where protection measures are taken in health institutions. In patients who undergo DAA treatment, the follow-up should be carried out by health institutions that do not provide pandemic services, and if necessary, telemedicine should be used.
APA, Harvard, Vancouver, ISO, and other styles
16

Artemova, M. G., and D. T. Abdurakhmanov. "Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects." Terapevticheskii arkhiv 89, no. 4 (2017): 110–14. http://dx.doi.org/10.17116/terarkh2017894110-114.

Full text
Abstract:
Cryoglobulinemia (CG) is detected in more than 50% of patients with chronic hepatitis C (CHC); however, only 15—25% of them develop cryoglobulinemic vasculitis (CV) that is a systemic vasculitis due to the formation of immune deposits, which affects small (less than medium-sized) vessels and which is frequently fatal for the patient. The causes of CG only in some patients with CHC and the pathogenesis of CV remain unstudied; however, the accumulated data allow one to identify the special contribution of the patient’s genetic factors to the development of the disease. The paper considers the genetic aspects of the development of CG and CV in CHC.
APA, Harvard, Vancouver, ISO, and other styles
17

Mousa, Nasser, Yahia Gad, Azza Abdel-Aziz та Ibrahem Abd-Elaal. "Increasedα-Fetoprotein Predicts Steatosis among Patients with Chronic Hepatitis C Genotype 4". International Journal of Hepatology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/636392.

Full text
Abstract:
Background. The prognostic importance of α-fetoprotein (AFP) level elevation in patients with chronic hepatitis C and its clinical significance in steatosis associated with HCV infection remain to be determined. The present paper assessed clinical significance of elevated AFP in patients with CHC with and without steatosis.Methods. One hundred patients with CHC were divided into 50 patients with CHC and steatosis and 50 patients with CHC and no steatosis based on liver biopsy.Results. AFP was significantly increased in CHC with steatosis than patients without steatosis (P<0.001). Highly significant positive correlation was found between serum AFP and necroinflammation as well as the severity of fibrosis/cirrhosis and negative significant correlation with albumin level in chronic HCV with steatosis (P<0.001) but negative nonsignificant correlation with ALT and AST level (P≤0.778and0.398), respectively. Highly significant increase was found in chronic hepatitis patients with steatosis than CHC without steatosis regarding necroinflammation as well as the severity of fibrosis/cirrhosis and AFP (P<0.001).Conclusion. Patients with chronic HCV and steatosis have a higher AFP levels than those without steatosis. In chronic HCV with steatosis, elevated AFP levels correlated positively with HAI and negative significant correlation with albumin level.
APA, Harvard, Vancouver, ISO, and other styles
18

Kukla, Michał, Brygida Adamek, Marek Waluga, et al. "HepaticChemerinandChemokine-Like Receptor 1Expression in Patients with Chronic Hepatitis C." BioMed Research International 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/517820.

Full text
Abstract:
Introduction. Chemerin seems to be involved in pathogenesis of chronic hepatitis C (CHC). Hepatic expressions of chemerin and its receptor, chemokine receptor-like 1 (CMKLR1), in CHC have not been studied so far.Aim. To evaluatechemerinandCMKLR1hepatic expression together with serumchemerinconcentration in CHC patients and to assess their relationship with metabolic and histopathological abnormalities.Methods. The study included 63 nonobese CHC patients. Transcription ofchemerinandCMKLR1was assessed by quantitative real-time PCR, while serum chemerin was assessed by enzyme-linked immunosorbent assay.Results. Expression ofchemerinandCMKLR1was present in the liver of all CHC patients regardless of sex or age. This expression was not associated with necroinflammatory activity and steatosis grade, fibrosis stage, and metabolic abnormalities. There was a negative association between serum chemerin andchemerinhepatic expression (r= (−0.41),P= 0.006).Conclusion. The study for the first time confirmed a marked expression ofchemerinandCMKLR1in the liver of CHC patients. The study was performed using the homogenates of human liver tissue, so it is not possible to define whether hepatocytes or other cell types which are abundantly represented in the liver constitute the main source ofchemerinandCMKLR1mRNA.
APA, Harvard, Vancouver, ISO, and other styles
19

Nikiforova, A. O., V. A. Greshnyakova, A. A. Zhirkov, and L. A. Alekseeva. "Lipid and carbohydrate metabolism disturbances in children with chronic hepatitis C." Journal Infectology 16, no. 4 (2024): 63–70. http://dx.doi.org/10.22625/2072-6732-2024-16-3-63-70.

Full text
Abstract:
Aim. To study the state of lipid and carbohydrate metabolism, body composition, liver parenchyma structure in children with chronic hepatitis C (CHC).Materials and methods. 63 children with CHC examined at DNACIB in 2022–2023 (anthropometry, laboratory examination, bioimpedance analysis (BIA) of body composition, liver elastography with evaluation of steatosis).Results. Abnormalities of lipid metabolism were detected in 1/3 of children with CHC even with normal and low body mass index (BMI). Signs of insulin resistance (HOMAIR>3,2) were found in 54% of children with CHC. One third of patients with insulin resistance have liver steatosis, which significantly exceeds the frequency of steatosis registration among children without insulin resistance. There was a tendency for the frequency of insulin resistance to increase in proportion to the progression of the stage of liver fibrosis. No association between hepatitis virus genotype and disorders of lipid and carbohydrate metabolism was found.Conclusion. As a result of hepatitis C virus exposure in children with CHC, the risk of insulin resistance formation increases, which may be one of the pathogenetic mechanisms of liver steatosis development, increasing the risk of severe liver fibrosis formation and unfavorable outcome of the disease.
APA, Harvard, Vancouver, ISO, and other styles
20

Mehmet Sait, Bugdaci, Karaca Cetin, Koksal Ali Rıza, Boga Salih, Alkim Canan та Sokmen Mehmet. "The association with histopathological findings and predictive significance of transforming growth factor beta 1 (TGF β1) in patients with chronic viral hepatitis". Archives of Hepatitis Research 9, № 1 (2023): 005–10. http://dx.doi.org/10.17352/ahr.000035.

Full text
Abstract:
Background: Chronic Viral Hepatitis (CVH) is the most common cause of hepatocellular cancer and cirrhosis related to liver fibrosis. The gold standard in the diagnosis of fibrosis is liver biopsy. TGF β1 is a pleiotropic cytokine that plays a pivotal role in carcinogenesis and fibrosis. The results of studies investigating the relationship between TGF β1 and histopathological findings are controversial. We aimed to investigate the relationship between TGF β1 and histopathological findings. Methods: Patients with Chronic Hepatitis B (CHB) and C (CHC), Non-Alcoholic Steatohepatitis (NASH), inactive HBsAg carriers, patients with cirrhosis and healthy control cases presenting to the Gastroenterology Clinic of Sisli Etfal Training and Research Hospital between 2009-2010 were included in the study. Laboratory tests, HCV RNA, HBV DNA, viral load, and viral markers (such as HBsAg, anti-HCV) were determined. Biopsies were performed on patients with hepatitis B and C, and non-alcoholic steatohepatitis (NASH). Histologic features were defined as Histologic Activity Index (HAI) and fibrosis stage (Knodell’s scoring). TGF β1 was evaluated by the ELISA method. Results: 267 cases including 44 non-alcoholic steatohepatitis cases [27 female (57%)], 38 inactive HBsAg carriers [23 female (60%)], 48 patients with chronic hepatitis B [17 female (35%)], 27 chronic hepatitis C [14 female (60%)], 15 decompensated cirrhosis [3 female (20%)] and 94 healthy control cases were included in the study. Compared with healthy controls, all other subgroups had significantly elevated TGF β1 levels. TGF β1 was found to have a specificity of 93.6% and a sensitivity of 88.9% (AUC: 0.948, 95% CI: 0.916-0.981) in determining liver diseases. TGF β1 had a positive correlation with fibrosis and histological activity index in patients with CHB and CHC. There was a negative correlation between TGF β1 and HBV DNA and HCV RNA. TGF β1 had a significant correlation with LDL and total cholesterol in cases with CHB and CHC. Conclusion: TGF β1 is correlated with both HAI and fibrosis in patients with CHB and CHC. TGF β1 might have a role in the prognostic significance of elevated LDL levels and low viral load in patients with CHC.
APA, Harvard, Vancouver, ISO, and other styles
21

Shchanitcyna, S. E., E. Z. Burnevich, E. N. Nikulkina, A. L. Filatova, S. V. Moiseev, and N. A. Mukhin. "Risk factors of unfavorable prognosis of chronic hepatitis C." Terapevticheskii arkhiv 91, no. 2 (2019): 59–66. http://dx.doi.org/10.26442/00403660.2019.02.000082.

Full text
Abstract:
Aim. To investigate risk factors of unfavorable prognosis in patients with chronic hepatitis C (CHC), including liver cirrhosis (LC), decompensated cirrhosis, hepatocellular carcinoma (HCC), cryoglobulinemic vasculitis (CryoVas) and B-cell non-Hodgkin’s lymphoma. Materials and methods. This was a retrospective study using data of 824 patients with CHC hospitalized between 2010 and 2016 in clinic named after E.M. Tareev. We used multivariate analysis including logistic regression to calculate odds ratios (ORs) for potential risk factors/predictors associated with unfavorable outcomes in patients with CHC. Results and discussion. The rate of LC, decompensated LC, HCC, serious CryoVas and B-cell lymphoma in patients with CHC was 39.1% (322/824), 14.0% (115/824), 2.8% (23/824), 5.2% (43/824) and 1.2% (10/824), respectively. After adjustment for sex and age the rate of LC, decompensated LC, HCC was 22.8, 8.0 and 1.5%, respectively. Annual rate of LC in patients with CHC was 1.5%; in cirrhotic patients annual rate of decompensated LC and HCC was 2.9 and 1%, respectively. Risk factors independently associated with development of LC were elevated body mass index (OR 1.43), immunosuppressive therapy (OR 1.67), diabetes type 2 (OR 2.03), absence of antiviral therapy (OR 2.15), alcohol abuse (OR 2.34), duration of infection ≥20 years (ОR 2.74) and an absence of sustained virological responce (SVR) (OR 2.98). Independent risk factors for decompensation in cirrhotic patients included diabetes type 2 (OR 1.47), alcohol abuse (OR 1.53), an absence of antiviral therapy (OR 2.36) and an absence of SVR (OR 1.94). An episode of decompensation was the independent predictor of HCC in cirrhotic patients (OR 3.99). Genotype 1b (OR 1.66) and an absence of antiviral therapy (OR 3.31) were independently associated with serious CryoVas. Two prognostic scales were offered for risk evaluation of LC and its complications. Conclusions. Multivariate analysis showed several factors independently associated with higher risk for LC, decompensation of LC, HCC, serious CryoVas in patients with CHC. The rate of unfavorable outcomes of CHC is found, including rare extrahepatic manifestations.
APA, Harvard, Vancouver, ISO, and other styles
22

Chulanov, V. P., A. P. Zueva, D. S. Kostyushev, S. A. Brezgin, E. V. Volchkova, and V. V. Maleyev. "Hepatitis C can be cured: will hepatitis B become next?" Terapevticheskii arkhiv 89, no. 11 (2017): 4–13. http://dx.doi.org/10.17116/terarkh201789114-13.

Full text
Abstract:
Chronic hepatitis B (CHB) and C (CHC) are one of the leading causes of cirrhosis and liver cancer with over a million of people dying annually from their consequences. In Russia CHB and CHC morbidity and related mortality show an upward trend. As a result of recent breakthroughs in antiviral therapeutics CHC became a curable disease. Modern therapeutics effectively suppress viral replication in CHB patients, but withdrawal of antivirals usually results in disease relapse. Loss of HBsAg required for the so called «functional cure» is a very rare event. Moreover, «complete cure» when the virus is entirely eliminated from the body is not possible due to a persistent form of covalently closed circular DNA (cccDNA) of hepatitis B virus (HBV) in hepatocytes refractory to modern antivirals. Today, there is a plethora of new promising medications being at different stages of development that target different steps of viral life cycle, including inhibitors of interaction between HBV and its entry receptor NTCP, inhibitors of HBV cccDNA, inhibitors of nucleocapsid assembly, technologies of genome editing (TALENs, CRISPR/Cas etc) and RNA-interference. In addition to direct acting antivirals, there is a number of approaches aimed at enhancement of the innate and adaptive immune responses. In experimental conditions, some of these approaches or their combinations help to achieve functional cure. However, complete elimination of the virus is possible only using technologies of genome editing, capable of specific cccDNA degradation. Nuclease systems are currently at their early stages of development, and there is a long way to prove their efficacy and safety. Nevertheless, highly promising results of the recent years leave no doubt that CRISPR/Cas systems and similar technologies can become the basis of CHB therapy.
APA, Harvard, Vancouver, ISO, and other styles
23

El-Mesallamy, Hala O., Nadia M. Hamdy, Hanan H. Rizk, and Abdel-Rahman El-Zayadi. "Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C." Mediators of Inflammation 2011 (2011): 1–7. http://dx.doi.org/10.1155/2011/703031.

Full text
Abstract:
Objective. Highlighting the apelin system would present a new therapeutic target for liver disease. Apelin; endogenous ligand for the orphan receptor APJ, was recently suggested to be associated with fibrosis progression and cirrhosis in addition to insulin resistance (IR) and inflammation. The present study was conducted to evaluate blood apelin level changes among 73 chronic hepatitis C (CHC) Egyptian patients and if associated with body mass index (BMI), IR, and tumor necrosis factor-alpha (TNF-α). Serum apelin levels were significantly higher in patients with CHC with median value (3.25) when compared with controls (1.11), atP<0.0001, with significant apelin variations among asymptomatic carriers (ASC), fibrosis, and cirrhosis patients, and also among obese and nonobese patients. Multiple regression analysis depicted that BMI, triglycerides, and total cholesterol were independent correlation factors to apelin levels, whereas TNF-αwas found to be significantly negatively correlated to adjusted apelin in CHC patients (r=−0.5944,P<0.0001). IR was positively correlated to adjusted apelin in CHC patients (r=0.2663,P<0.05).Conclusion. Apelin level varies among stages of CHC, which may contribute to fibrosis progression. In addition, obesity and IR could act as comorbid factors affecting apelin level in patients with CHC.
APA, Harvard, Vancouver, ISO, and other styles
24

Jeenalieva, G. M. "THE SIGNS OF CARBOHYDRATE-LIPID METABOLISM DISTURBANCE IN PATIENTS WITH CHRONIC HEPATITIS C." Hepatology and Gastroenterology 5, no. 1 (2021): 56–60. http://dx.doi.org/10.25298/2616-5546-2021-5-1-56-60.

Full text
Abstract:
Background. Viral hepatitis C (CHC) is an urgent problem due to its prevalence, high risk of developing liver cirrhosis and hepatocellular carcinoma. Viral hepatitis C can cause disruption of many biochemical processes in the liver cells, primarily that of carbohydrate - lipid metabolism. Objective. To study carbohydrate-lipid metabolism disturbances in patients with CHC. Material and methods. The study included 124 patients with paucisymptomatic chronic hepatitis C. The metabolic syndrome was diagnosed according to the indicators recommended by the Committee of Experts of the Russian Society of Cardiology (2007). Results. The parameters of lipid metabolism were studied in 52 of 124 patients with CHC. 29 of 52 patients with CHC (55.7%) showed a decrease in HDL cholesterol and an increase in LDL cholesterol, including a 2- fold increase in VLDL. The metabolic syndrome was detected in 22.5% of patients with CHC, 62.9% of patients had the manifestations of dyslipidemia (steatosis or steatohepatitis of the liver, obesity, arterial hypertension, insulin resistance, type 2 diabetes mellitus). Conclusions. In patients with CHC, carbohydrate-lipid metabolism disturbance was revealed as an integral indicator of metabolic syndrome, its incidence rising with the increase in activity and duration of the infectious process.
APA, Harvard, Vancouver, ISO, and other styles
25

Lin, Ming-Chieh, Chia-Yen Dai, Chung-Feng Huang, et al. "Itemization difference of patient-reported outcome in patients with chronic liver disease." PLOS ONE 17, no. 2 (2022): e0264348. http://dx.doi.org/10.1371/journal.pone.0264348.

Full text
Abstract:
Background and aims The itemization difference of patient-reported outcome (PRO) in hepatitis patients with different etiologies remains elusive in Asia. We aimed to assess the characteristics and the difference of health-related quality of life (HRQoL) in chronic hepatitis B (CHB), chronic hepatitis C (CHC), and non-alcoholic fatty liver disease (NAFLD) patients. Methods We conducted the study in an outpatient setting. The 36-Item Short Form Health Survey (SF-36) was completed by the patients upon the initial diagnosis and recruitment for a long-term follow-up purpose. The PRO results were also assessed by disease severity. Results There were 244 patients (198 males) of CHB, 54 patients (29 males) of CHC, and 129 patients (85 males) of NAFLD, respectively. CHC patient had the mean score of 67.1 ± 23.3 in physical component summary (PCS) of the SF-36 health survey, which was significantly lower than CHB patients (76.4 ± 19.5), and NAFLD patients (77.5 ± 13.7), respectively (p = 0.001). The significantly lower performance of PCS in CHC patients was mainly attributed to the lower performance in physical functioning and bodily pain components. Higher fibrosis 4 index scores were significantly associated with lower PCS scores in all patient groups. There was no significant difference of mean mental component summary (MCS) between groups. However, NAFLD patients had significantly lower mental health scores than other groups (p = 0.02). Conclusions The significant difference of HRQoL exists in hepatitis patients with different etiologies. Disease severity leads to a lower PCS performance.
APA, Harvard, Vancouver, ISO, and other styles
26

Barbu, Ecaterina-Constanta, Cristina-Emilia Chitu-Tisu, Mihai Lazar, et al. "THE EFFECT OF CHRONIC VIRAL HEPATITIS B AND C ON BONE MINERAL DENSITY." Romanian Journal of Infectious Diseases 18, no. 4 (2015): 138–42. http://dx.doi.org/10.37897/rjid.2015.4.3.

Full text
Abstract:
Objectives. Chronic viral hepatitis B and C represent an important health burden all over the world. Reduced bone mineral density is an extrahepatic complication which has been found in patients with chronic liver disease. The aim of our study was to identify bone mineral impairment (osteopenia/osteoporosis) and the risk factors that are correlated with its severity, in patients with chronic viral hepatitis B (CHB) and C (CHC). Material and methods. Anthropometric, biological parameters and bone mineral density (BMD) were measured in 60 patients with CHB (n = 30) and CHC (n = 30). BMD was assessed using Dual Energy X-ray Absorptiometry (DEXA) in the hip and lumbar spine regions, inclusively a whole scan (total body). Results. Sixty patients (mean age 44.93 years, range: 20-70) were enrolled, including 30 CHB patients (mean age 46.43 years, range: 20-70) and 30 CHC patients (mean age 43.43 years, range: 28-64). Forty of patients were men (66.66 %). Active smokers were 16 patients (26.66 %). Meanbody mass index (BMI) was 25.38 kg/m2 (range: 16.70-38.40). At baseline, 21 of 60 (35%) of the patients had evidence of osteopenia and 4 of 60 (6.66%) of patients, respectively presented osteoporosis at LS. At total hip, 22 of 60 of the patients (36.66%) recorded osteopenia; osteoporosis was found at 7 patients (11.66%) at total hip assessment. Low BMD values at different regions correlated significantly with low BMI, smoking and liver fibrosis grade. Conclusions. Our results suggest that bone mineral metabolism disorders exist in patients with chronic viral hepatitis B and C who are active smokers, presenting low BMI and advanced liver fibrosis, even without liver cirrhosis.
APA, Harvard, Vancouver, ISO, and other styles
27

Hairullina, Aygul K., Milyausha F. Kabirova, Larisa P. Gerasimova, and Rasima R. Haibullina. "Dental status of patients with chronic hepatitis C." Russian Journal of Dentistry 25, no. 4 (2022): 345–50. http://dx.doi.org/10.17816/1728-2802-2021-25-4-345-350.

Full text
Abstract:
BACKGROUND: The high prevalence of chronic hepatitis C (CHC) makes it a serious public health issue, and this is further aggravated by the increased incidence of associated oral mucosal diseases.
 AIM: To assess the dental status of patients with chronic viral hepatitis.
 MATERIAL AND METHODS: A comprehensive dental examination of 48 patients with a confirmed diagnosis of CHC was carried out. The study group was classified based on the Knodell index of histological activity of chronic hepatitis, as follows: (1a) mild process activity (48 points; n=20); and (1b) moderate process activity (912 points; n=28 patients). The comparison group consisted of 30 apparently healthy individuals (16 men, 14 women; age: 2836 years) with no evidence of any somatic pathology following a professional medical examination.
 RESULTS: A comprehensive dental examination of patients with chronic hepatitis C showed evidence of gingival bleeding when brushing teeth, bad breath, erosions in the oral mucosa, and a high prevalence of severe periodontal inflammation. The most common diseases observed in this group included recurrent aphthous stomatitis, candidiasis, and chronic herpetic stomatitis, all of which were accompanied by severe pain.
 CONCLUSION: The auto-fluorescence study showed preclinical signs of hyperkeratotic changes in the dental area in approximately 21.21.6% of the study group. A correlation between the frequency and severity of symptoms of dental diseases and the degree of underlying CHC disease activity was seen.
APA, Harvard, Vancouver, ISO, and other styles
28

Christen, Verena, Francois Duong, Christine Bernsmeier, Dianxing Sun, Michael Nassal, and Markus H. Heim. "Inhibition of Alpha Interferon Signaling by Hepatitis B Virus." Journal of Virology 81, no. 1 (2006): 159–65. http://dx.doi.org/10.1128/jvi.01292-06.

Full text
Abstract:
ABSTRACT Alpha interferon (IFN-α) and pegylated IFN-α (pegIFN-α) are used for the treatment of chronic hepatitis B (CHB). Unfortunately, only a minority of patients can be cured. The mechanisms responsible for hepatitis B virus (HBV) resistance to pegIFN-α treatment are not known. pegIFN-α is also used to treat patients with chronic hepatitis C (CHC). As with chronic hepatitis B, many patients with chronic hepatitis C cannot be cured. In CHC, IFN-α signaling has been found to be inhibited by an upregulation of protein phosphatase 2A (PP2A). PP2A inhibits protein arginine methyltransferase 1 (PRMT1), the enzyme that catalyzes the methylation of the important IFN-α signal transducer STAT1. Hypomethylated STAT1 is less active because it is bound by its inhibitor, PIAS1. In the present work, we investigated whether similar molecular mechanisms are also responsible for the IFN-α resistance found in many patients with chronic hepatitis B. We analyzed the expression of PP2A, the enzymatic activity of PRMT1 (methylation assays), the phosphorylation and methylation of STAT1, the association of STAT1 with PIAS1 (via coimmunoprecipitation assays), the binding of activated STAT1 to interferon-stimulated response elements (via electrophoretic mobility shift assays), and the induction of interferon target genes (via real-time RT-PCR) in human hepatoma cells expressing HBV proteins as well as in liver biopsies from patients with chronic hepatitis B and from controls. We found an increased expression of PP2A and an inhibition of IFN-α signaling in cells expressing HBV proteins and in liver biopsies of patients with CHB. The molecular mechanisms involved are similar to those found in chronic hepatitis C.
APA, Harvard, Vancouver, ISO, and other styles
29

Kireyev, I.V., and N.V. Zhabotynska. "Modern pharmacotherapy of chronic hepatitis C in patients who failed to achieve sustained virologic response." Annals of Mechnikov Institute, no. 2 (June 8, 2020): 35–38. https://doi.org/10.5281/zenodo.3885075.

Full text
Abstract:
Introduction. According to WHO experts, about 150 million people suffer from chronic viral hepatitis C (CHC), and 350,000 die annually as a result of liver damage by the hepatitis C virus (HCV). Ukraine is one of the countries with medium prevalence of CHC – about 3% of citizens are infected. CHC has become a treatable disease with the use of antiviral drugs (> 95%). To date, for the pharmacotherapy of CHC, a combination of pegylated interferon (PEG-IFN) with ribavirin and direct-acting antivirals (DAAs) are used. Pharmacotherapy of СHC using a combination of PEG-IFN and ribavirin has a relatively high efficiency, but it depends on the genotype of the HCV. Therefore, the use of DAAs is a priority in pharmacotherapy of chronic hepatitis C. Patients who failed to achieve sustained virologic response (SVR) are given a second course of treatment (retreatment). The decision on this is based on the following main positions: the nature of the previous response, the type of previous therapy and the potential for a new type of treatment, the severity of liver damage, the genotype of the virus and the presence of other prognostic factors and tolerance to previous therapy. Material & methods. The article analyzes the recommendations of the American Society of Infectious Diseases (IDSA) and the American Association for the Study of Liver Diseases (AASLD), in collaboration with the US International Anti-Virus Society (IAS-USA), as well as the WHO recommendation for repeated pharmacotherapy of CHC in patients who failed to achieve SVR. Results & discussion. To date, for re-treatment of CHC in patients receiving treatment without achieving a SVR, the different re-treatment regimens are recommended depending on the genotype of the HCV. An important problem during pharmacotherapy of patients with CHC is resistance to antiviral therapy. The amino acid polymorphism of NS3, NS5A and NS5B viral proteins in different HCV genotypes and subtypes, as well as the same strains of genotypes and subtypes that reduce DAAs efficacy, is referred to as resistance-related variants (RRV). However, antiviral therapy fails only when RRV is combined with other factors and features of the patient's body, decreased sensitivity to antiviral therapy, or insufficient duration of therapy. As seen in the recommendations for recurrent CHC pharmacotherapy, possible resistance to the protease inhibitor NS5A and to the NS3 protease inhibitors was considered. Conclusion. The results obtained from published sources indicate that current strategies for recurrent pharmacotherapy of CHC patients in most cases of unsuccessful pre-treatment allow the achievement of SVR using DAAs during re-treatment, including those regimens that have efficacy in resistance-associated variants.
APA, Harvard, Vancouver, ISO, and other styles
30

Булатова, И. А., Т. П. Шевлюкова, А. П. Щёкотова, and А. В. Кривцов. "Genetic profile of patients with chronic hepatitis C." Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia», no. 1 (March 31, 2022): 35–43. http://dx.doi.org/10.25557/0031-2991.2022.01.35-43.

Full text
Abstract:
Введение. Хронический гепатит С (ХГС) является мультифакториальным заболеванием, в формировании которого имеют значение генетические факторы возбудителя (вирус), хозяина и условия внешней среды. В настоящее время приоритетной областью здравоохранения является оценка роли генетических маркеров при многофакторных заболеваниях. Цель - оценка роли генетических маркеров при хроническом гепатите С. Методика. Обследовано 95 больных ХГС и 50 здоровых доноров. Оценивали концентрацию васкулоэндотелиального фактора роста (vascular endothelial growth factor - VEGF), фактора некроза опухоли (tumor necrosis factor alpha -TNF-α), активность ферментов каталазы (catalase - CAT), глутатионпероксидазы (glutathione peroxidase - GPX) в сыворотке крови. Также изучали полиморфизм генов VEGFA в регионе -634G/C, TNF-α в регионе -308G/A, CAT в регионе -262G/A, GPX4 в регионе -718С/Т и IL28B в регионе C/T и оценивали генетический профиль в баллах от 0 до 10 путем суммации аллелей риска. Результаты. Развитие ХГС сопровождается активацией процессов воспаления и неоангиогенеза с повышением концентрации и TNF-α (р<0,001), и VEGF (р<0,001) при истощении ферментов антиоксидантной защиты со снижением активности CAT (р<0,001) и GPX (р<0,001). Носительство аллели С гена VEGFA в регионе -634G/C в виде генотипа СС может является фактором риска развития ХГС (χ2=7,52; р=0,01). Выявлена ассоциация полиморфизма гена CAT (G262A) и GPX4 (С718Т) со снижением активности антиоксидантных ферментов. При оценке генетического профиля в группе здоровых 86% имели низкий риск развития ХГС (0-3 балла по шкале), а среди пациентов с ХГС - 68%. При этом 32% лиц с ХГС имели умеренный риск (4-7 баллов), а у доноров эта цифра была ниже и составила 14%. Оценка генетического профиля здоровых доноров и пациентов с ХГС, показала, что среди больных ХГС чаще встречались лица, имеющие одновременно большее количество аллелей риска. Заключение. Определение генетического профиля с использованием, TNF-α в регионе -308G/A, CAT в регионе -262G/A, GPX4 в регионе -718С/Т, VEGFA в регионе -634G/C и IL28B в регионе C/T позволяет оценить риск развития и прогрессирования ХГС. Introduction. Chronic hepatitis C (CHC) is a multifactorial disease. In its formation, the genetic factors of the pathogen (virus) and of the host, as well as the environmental conditions are important. Currently, a public health priority is the assessment of the role of genetic markers in multifactorial diseases. Aim - assessment of the role of genetic markers in chronic hepatitis C. Methods. We examined 95 patients with CHC and 50 healthy subjects. The concentrations of vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) were measured in blood serum. The enzymatic activities of catalase (CAT), glutathione peroxidase (GPX), and vascular endothelial growth factor (VEGF) were also evaluated. We also studied polymorphism of the VEGFA genes in the -634G/C region, TNF-α in the -308G/A region, CAT in the -262G/A region, GPX4 in the -718C/T region and IL28B in the C/T region, and we assessed the genetic profile in points from 0 to 10 by summing risk alleles. Results. The development of CHC was accompanied by activation of inflammation and neoangiogenesis with an increase in the concentration of both TNF-α (p < 0.001) and VEGF (p < 0.001) along with depletion of antioxidant defense enzymes, and with a decrease in the activity of CAT (p < 0.001) and GPX (p < 0.001). Carriage of the C allele of the VEGFA gene in the -634G/ C region in the form of the CC genotype may be a risk factor for the development of CHC (χ2 = 7.52; p = 0.01). An association of CAT (G262A) and GPX4 (C718T) gene polymorphism with a decrease in the activity of antioxidant enzymes was found. According to their genetic profile, 86% of the healthy subjects had a low risk of developing CHC (0-3 points on the scale), whereas 68% patients with CHC had a low risk. Furthermore, 32% of patients with CHC had a moderate risk (4-7 points), whereas in healthy subjects, this percentage was almost 50% less (14%). Evaluation of the genetic profiles of healthy subjects and of patients with CHC showed that patients with CHC were more likely to have a greater number of risk alleles. Conclusion. Evaluation of the genetic profile using TNF-α in the -308G/A region, CAT in the -262G/A region, GPX4 in the -718C/T region, VEGFA in the -634G/C region and IL28B in the C/T region allows assessment of the risk of the development and the progression of CHC.
APA, Harvard, Vancouver, ISO, and other styles
31

Kim, Young Woon, Jung Hyun Kwon, Jeong Won Jang, et al. "Diagnostic Usefulness of Real-Time Elastography for Liver Fibrosis in Chronic Viral Hepatitis B and C." Gastroenterology Research and Practice 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/210407.

Full text
Abstract:
The aim of this study was to investigate the diagnostic usefulness of real-time elastography (RTE) for liver fibrosis in chronic viral hepatitis B (CHB) and C (CHC). Fifty-one and thirty-two of the patients were diagnosed with CHB and CHC, respectively. Enrolled patients underwent liver biopsy and RTE. The FIB-4 index and aspartate transaminase-to-platelet ratio index (APRI) were also measured. The liver fibrosis index (LFI) by RTE increased significantly with the Knodell fibrosis stage:3.14±0.62for F0,3.28 ± 0.42for F1,3.43 ± 0.53for F3, and4.09 ± 1.03for F4 (P=0.000). LFI as well as APRI, FIB-4, platelet, albumin, and prothrombin time showed the difference in patients with advanced fibrosis (≥F3) and those with mild fibrosis (≤F1). In addition, RTE had better discrimination power between≥F3 and F4 than between FIB-4 and APRI. In CHC patients, the area under receiver operating characteristic curves of RTE for advanced fibrosis was higher than that in CHB patients (0.795 versus 0.641). RTE is useful for the assessment of advanced fibrosis in patients with CHB and CHC and has better discrimination power than other serologic markers.
APA, Harvard, Vancouver, ISO, and other styles
32

Jordović, Jelena, Ksenija Bojović, Jasmina Simonović-Babić, et al. "Significance of UGT1A1∗28 genotype in patients with advanced liver injury caused by chronic hepatitis C." J Med Biochem 38, no. 1 (2018): 45–52. https://doi.org/10.2478/jomb-2018-0015.

Full text
Abstract:
Background: Chronic hepatitis C (CHC) is a significant cause of liver related morbidity and mortality worldwide. The role of genetics in the host response to hepatitis C virus is not elucidated. Genetic variations in UGT1A1 gene are the most common cause of hereditary unconjugated hyperbilirubinemia-Gilbert syndrome. This is the first study investigating the association of UGT1A1 TA repeats promoter genotypes with the degree of liver injury, viremia and biochemical markers in CHC patients with advanced liver injury and late virological relapse. Methods: Genetic testing of UGT1A1 TA repeats promoter genotypes was performed in 42 CHC patients with advanced fibrosis and cirrhosis who achieved sustained virological response and 42 healthy blood donors. CHC patients were evaluated for clinical findings, laboratory tests and imaging. Results: UGT1A1*28 genotype (7/7 TA repeats) was observed in 23.8% CHC patients and 16.7% healthy controls with no significant difference in genotype frequencies (p=0.49). Pretreatment levels of ferritin and bilirubin were associated with the presence of UGT1A1*28 genotype, indicating its potential as a predictive marker. However, in our study, there was no correlation of UGT1A1*28 genotype with the degree of fibrosis or viremia. During antiviral treatment, dose reductions and treatment interruptions, as well as treatment success and occurrence of late virological relapse were not related to the presence of UGT1A1*28 genotype in CHC patients with severe liver injury. Conclusions: Frequencies of UGT1A1*28 genotype are high in both Serbian CHC patients and healthy subjects. The presence of UGT1A1*28 genotype was not associated with ribavirin-related adverse effects and had no effect on long term outcome in CHC patients.
APA, Harvard, Vancouver, ISO, and other styles
33

Kostic, Marina, Biljana Kocic, and Branislav Tiodorovic. "Stigmatization and discrimination of patients with chronic hepatitis C." Vojnosanitetski pregled 73, no. 12 (2016): 1116–24. http://dx.doi.org/10.2298/vsp150511135k.

Full text
Abstract:
Background/Aim. Chronic hepatitis C (CHC) is often associated with injectable drug users and human immunodeficiency virus coinfection for which there is stigmatization in society. The aim of this study was to identify the presence of stigma and discrimination of patients with CHC, as well as the influence of sociodemographic factors on the occurrence of stigmatization. Methods. A cross-sectional study was performed. Patients with CHC and conducted antiviral therapy completed an anonymous structured questionnaire consisting of sociodemographic questions and Hepatitis C stigma scale. Results. Out of 154 patients 61.7% were male and 72.1% from the city; 59.7% have completed secondary school; 61.7% were employed before the disease while 31.8% after the disease; 45.5% were unsatisfactory with financial situation; 54.5% were married; 37.7% lived with a spouse and children; 86.4% in their own house/apartment; 5.2% of the patients were abandoned by their partners, while 35.7% consumed drugs. A statistical significance of the stigma score was found in those who lived in the city (p = 0.018), unmarried (p = 0.005), abandoned by the partners after the diagnosis of CHC (p < 0.001), drug users (p = 0.002) and those living with parents (p = 0.034). Univariate regression analysis singled out as significant: residence (p = 0.018), living with their parents (p = 0.046), abandonment by a partner (p < 0.001) and drug use (p = 0.002). A multivariate regression model of independent variables singled out abandonment by partners (Beta = 5.158, p = 0.007). Men disagree significantly with the two elements inside stigma [not the same as the others (p = 0.035)] and hurt by the reaction of others (p = 0.047)). Conclusion. The presence of stigma in patients with CHC was proven. The results indicate the need to strengthen anti-stigma programs that will reduce their psychological and social problems and reduce stigmatization in society.
APA, Harvard, Vancouver, ISO, and other styles
34

., Manjri, Virender Katyal, Deepak Yadav, and Sandeep Goyal. "Screening beyond conventional serological markers for hepatitis B and C viruses in cirrhosis: an entity overlooked." International Journal of Research in Medical Sciences 8, no. 10 (2020): 3727. http://dx.doi.org/10.18203/2320-6012.ijrms20204261.

Full text
Abstract:
We aimed to emphasise the role of screening beyond conventional serological markers (HBsAg and Anti HCV antibodies for chronic viral hepatitis B and C respectively) in patients with cirrhosis. Patients with cirrhosis of liver are often labelled as having cryptogenic cirrhosis (CC), if no etiology is found. In chronic viral hepatitis B and C (CHB and CHC) induced cirrhosis, HBsAg and Anti HCV antibodies respectively are usually done to rule out the viral infections however their absence have been documented in subset of patients having these infections. In this regard, we hereby present a case labelled as CC and developed HCC; later on, further evaluation turned out to be having both CHB and CHC. A 51-year-old male with diabetes presented with index episode of hemetemesis. On further evaluation he was diagnosed to have cirrhosis of liver. No etiology was found and he was labeled as cirrhosis secondary to Non-alcoholic steatohepatitis (NASH)/cryptogenic cirrhosis. Later on, he developed hepatocellular carcinoma (HCC). We evaluated the patient with HBV DNA and HCV RNA levels keeping possibility of occult hepatitis B (OBI)/ seronegative hepatitis C infection despite HBsAg and Anti HCV antibodies being negative. Both levels were found to be raised and we attributed cirrhosis to dual hit by CHB and CHC. Patient was managed with antiviral drugs successfully with no recurrence of HCC and control of blood sugar levels. We hereby stress that screening beyond the HBsAg and Anti HCV antibodies should be done in all cases of liver cirrhosis in which etiology is not found on initial screening.
APA, Harvard, Vancouver, ISO, and other styles
35

Zuwała-Jagiello, Jolanta, Monika Pazgan-Simon, Krzysztof Simon, and Maria Warwas. "Picolinic Acid in Patients with Chronic Hepatitis C Infection: A Preliminary Report." Mediators of Inflammation 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/762863.

Full text
Abstract:
Macrophage activation seems to be a feature of chronic liver diseases. Picolinic acid (PA) as a macrophage secondary signal causes the activation of interferon-gamma- (IFN-γ-) prime macrophage and triggers cytokine-driven inflammatory reactions. The rationale for seeking increased PA formation in chronic viral hepatitis is based on the involvement of activated macrophages in chronic viral hepatitis-associated inflammation. The aim of this study was to determine serum PA levels in patients with chronic hepatitis C infection, taking into account the presence of diabetes. We assessed PA and high-sensitivity C-reactive protein (hsCRP) as a marker of inflammation in 51 patients with chronic hepatitis C infection (CHC), both with and without diabetes and 40 controls. Compared with the controls, the patients with CHC showed a significant increase in plasma concentrations of PA and hsCRP (P<0.01andP<0.05, resp.). The values of PA and hsCRP were more elevated in patients with diabetes than without diabetes (bothP<0.01). The positive relationships were between PA and hsCRP levels (P<0.05) and the presence of diabetes (P<0.001). We documented that significant elevation in serum PA levels is associated with diabetes prevalence and increased inflammatory response reflected in hsCRP levels in CHC patients.
APA, Harvard, Vancouver, ISO, and other styles
36

Dzemova, A. A., R. A. Ganchenko, G. F. Trifonova, and E. V. Esaulenko. "CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION AFTER STARTING THE HCV ELIMINATION PROGRAM." Hepatology and Gastroenterology 4, no. 2 (2020): 165–70. http://dx.doi.org/10.25298/2616-5546-2020-4-2-165-170.

Full text
Abstract:
Background. Five years have passed since the adoption of the strategy for the elimination of viral hepatitis. It is necessary to take stock of the frst results. Objective – to assess the dynamics of the epidemic process of CHC and the clinical manifestations of the disease during the period of 2015-2019. Material and methods. The article analyzes the data from the state statistical reporting of infectious diseases in the Russian Federation (RF), from the reference-center for the monitoring of viral hepatitis, from statistical tables compiled at Methodological and Research Center for Epidemiological Surveillance of Viral Hepatitis under Pasteur Institute of Epidemiology and Microbiology. The data from the Federal register of patients with viral hepatitis were used. The article analyzes our own experience of observing 555 patients with HCV at different stages of the disease. Results. In 2015–2019, CHC incidence in the RF decreased by 20% (30,90/0000- in 2019, 38,00/0000– in 2015). The total number of people with CHC is increasing (in 2015 – 562 622 people, in 2019 – 635372). It is estimated that only 20% of those infected are under surveillance. The death rate from CHC remains high. The proportion of patients with an advanced stage of CHC is about 20%. The proportion of decompensated cirrhosis decreased by 8%. In recent years, government funding for the treatment has increased, but only about 8% of all registered CHC patients are covered by the therapy. Conclusions. In the RF the WHO strategy targets have not been achieved by 2020. That’s why it’s important to develop a strategy to counter the spread of HCV for the period up to 2030.
APA, Harvard, Vancouver, ISO, and other styles
37

Surlin, Petra, Luminita Lazar, Cerasella Sincar, et al. "NLRP3 Inflammasome Expression in Gingival Crevicular Fluid of Patients with Periodontitis and Chronic Hepatitis C." Mediators of Inflammation 2021 (November 19, 2021): 1–8. http://dx.doi.org/10.1155/2021/6917919.

Full text
Abstract:
The study is aimed at assessing the impact that periodontal disease and chronic hepatitis C could have on gingival crevicular fluid levels of the NLRP3 inflammasome, caspase-1 (CASP-1), and interleukin-18 (IL-18) and at evaluating whether the increased local inflammatory reaction with clinical periodontal consequences is correlated to their upregulation. Patients were divided into four groups, according to their periodontal status and previously diagnosed hepatitis C, as follows: (i) CHC group, chronic hepatitis C patients; (ii) P group, periodontal disease patients, systemically healthy; (iii) CHC + P group, patients suffering from both conditions; and (iv) H group, systemically and periodontally healthy controls. Gingival crevicular samples were collected for quantitative analysis of the NLRP3 inflammasome, CASP-1, and IL-18. CHC + P patients expressed the worse periodontal status and the highest NLRP3, CASP-1, and IL-18 levels, the difference being statistically significant ( p < 0.05 ). The P group patients also expressed significantly more elevated NLRP3, CASP-1, and IL-18 levels, as compared to nonperiodontal patients (CHC and H groups). Chronic hepatitis C and periodontal disease could have a significant influence on the upregulation of NLRP3 inflammasome and its components, possibly contributing to an increased local inflammatory reaction and clinical periodontal consequences.
APA, Harvard, Vancouver, ISO, and other styles
38

Ferrari, Silvia Martina, Poupak Fallahi, Ilaria Ruffilli, et al. "Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?" Journal of Immunology Research 2019 (August 8, 2019): 1–11. http://dx.doi.org/10.1155/2019/5878960.

Full text
Abstract:
Chemokine (C-X-C motif) ligand (CXCL)10 and other CXCR3 chemokines are involved in the pathogenesis of acute and “chronic hepatitis C virus (HCV) infection” (CHC). Here, we review the scientific literature about HCV and CXCL10. The combination of circulating CXCL10 and single nucleotide polymorphisms (SNPs) in IL-28B can identify patients with acute HCV infection most likely to undergo spontaneous HCV clearance and those in need of early antiviral therapy. In CHC, the HCV and intrahepatic interferon- (IFN-) γ drive a raised CXCL10 expression by sinusoidal endothelium and hepatocytes, thereby inducing the recruitment of CXCR3-expressing T cells into the liver; thus, CXCL10 plays an important role in the development of necroinflammation and fibrosis. Increased CXCL10 was significantly associated with the presence of active vasculitis in HCV-associated cryoglobulinemia, or with autoimmune thyroiditis in CHC. Pretreatment CXCL10 levels are predictive of early virological response and sustained virological response (SVR) to IFN-α and ribavirin and may be useful in the evaluation of candidates for therapy. The occurrence of SNPs adjacent to IL-28B (rs12979860, rs12980275, and rs8099917), and CXCL10 below 150 pg/mL, independently predicted the first phase viral decline and rapid virological response, which in turn independently predicted SVR. Directly acting antiviral agents-mediated clearance of HCV is associated with the loss of intrahepatic immune activation by IFN-α, associated by decreased levels of CXCL10. In conclusion, CXCL10 is an important marker of HCV clearance and successful therapy in CHC patients. Whether CXCL10 is a novel therapeutic target in CHC will be evaluated.
APA, Harvard, Vancouver, ISO, and other styles
39

Tapdiya, Ganesh. "Advances in Antiviral Therapies for Chronic Hepatitis C: Improving Patient Outcomes." Innovations in Pharmacy Planet 12, no. 02 (2024): 28–33. https://doi.org/10.31690/ipplanet.2024.v012i02.008.

Full text
Abstract:
Chronic hepatitis C (CHC) is a major global health issue, with millions of people affected worldwide. The advent of direct-acting antivirals (DAAs) has revolutionized the management of CHC, offering higher cure rates and improved patient outcomes. This review explores the latest antiviral treatments for CHC, emphasizing the mechanisms of action, efficacy, and patient outcomes. DAAs such as sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and ledipasvir/sofosbuvir have demonstrated significant improvements in cure rates (exceeding 95%) and patient satisfaction due to fewer side effects and shorter treatment durations. These therapies have reduced the burden of liver disease, including cirrhosis and hepatocellular carcinoma. However, challenges such as drug resistance, accessibility, and affordability remain. The future of hepatitis C management lies in the development of pan-genotypic therapies, effective vaccines, and global initiatives to improve treatment accessibility.
APA, Harvard, Vancouver, ISO, and other styles
40

Kalyuzhin, O. V., Zh B. Ponezheva, I. V. Semenova, et al. "Lymphocyte subpopulations, levels of interferon, and expression of their receptors in patients with chronic hepatitis B and C: Correlation with the species of viruses and the degree of liver fibrosis." Terapevticheskii arkhiv 89, no. 11 (2017): 14–20. http://dx.doi.org/10.17116/terarkh2017891114-20.

Full text
Abstract:
Aim. To determine whether there is a correlation of the composition of circulating lymphocyte subpopulations, the serum concentrations of interferon (IFN)-α, IFN-γ, and IFN-λ3, and the lymphocyte expression of types I and II IFN receptors with the species of a disease pathogen and the degree of liver fibrosis (LF) in patients with chronic hepatitis B (CHB) and in those with chronic hepatitis C (CHC). Subjects and methods. The investigation enrolled 44 patients with CHC, 9 patients with CHB, and 13 clinically healthy donors. The degree of LF in the patients was determined using transient elastography. The composition of peripheral blood lymphocyte subpopulations was examined; the concentrations of IFN-α, IFN-γ, and IL-28B were estimated. Results. Lymphocyte counts were higher in patients with CHC and in those with CHB than those in healthy donors; and the number of neutrophils was lower. There were no differences between the groups in the composition of lymphocyte subpopulations with the exception of the number of CD3CD4cells, which in patients with CHC was larger than in those with CHB. In CHC and CHB patients, the counts of CD118lymphocytes were higher than those in healthy donors. Patients with CHB and those with CHC did not differ between themselves and from healthy donors in the expression of CD119 on the lymphocytes. In CHC patients, the relative CD119cell counts were higher between CD4lymphocytes than those in healthy donors. The serum levels of IFN-α and IFN-γ in CHC and CHB patients were similar, but higher in healthy donors. The concentration of IL-28B genotype in patients with CHC was twice as high as in those with CHB, but the differences were statistically insignificant. The number of lymphocytes increased with the progression of fibrosis; that of neutrophils decreased. There was an inverse relationship between platelet counts and LF severity. Multiple comparisons of the clusters of patients with different degrees of LF revealed no differences in the number of major lymphocyte subpopulations. However, the number of CD3CD16CD56natural killer-like T (NKT) cells correlated with fibrosis severity. Patients with different degrees of LF showed no differences in the proportion of CD118and CD119 cells between lymphocytes and in the serum levels of IFN-α, IFN-γ, and IL-28B levels. Patients with grade IV LF displayed a higher proportion of CD4CD119lymphocytes between CD45cells than did those with grade III LF. Conclusion. Several new clinical and laboratory trends were identified and the nature and extent of previously described hematological and immunological changes were clarified in CHC or CHB patients with various degrees of LF. Some indicators may be used as additional criteria for the prognosis of the above forms of hepatitis, and a number of newly described facts suggest that it is necessary to revise the protective/phlogogenic value of types I, II, and III IFNs in chronic viral hepatitis C and B.
APA, Harvard, Vancouver, ISO, and other styles
41

Schüler, Andreas, and Michael Peter Manns. "Patients with Chronic Hepatitis C - Who Should Not Be Treated?" Canadian Journal of Gastroenterology 14, suppl b (2000): 63B—67B. http://dx.doi.org/10.1155/2000/713251.

Full text
Abstract:
The decision to treat a patient with chronic hepatitis C (CHC) is based on what is known about the risk factors for developing liver cirrhosis or hepatocellular carcinoma, as well as on conditions that contraindicate therapy or impair therapy effectiveness. Several factors, including age, treatment side effects, disease severity, concurrent diseases and life conditions, may render treatment decisions more difficult. This review focuses on identifying CHC patients who should not receive treatment.
APA, Harvard, Vancouver, ISO, and other styles
42

Tkachenko, L. I., V. V. Maleev, and D. M. Sarieva. "LIPID METABOLISM DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C." Russian Archives of Internal Medicine, no. 6 (December 28, 2015): 50–56. http://dx.doi.org/10.20514/2226-6704-2015-0-6-50-56.

Full text
Abstract:
Purpose of the study. To study lipid metabolism in chronic hepatitis C and to assess its impact on the formation of insulin resistance, steatosis and progression of liver fibrosis.Materials and methods. The study included 205 patients with chronic hepatitis C (CHC). Conducts research, depending on the genotype C, viral load and body mass index (BMI) of the patients.Results. CHC patients revealed a combined hyperlipoproteinemia on the background of op-pression synthesis of apolipoproteins A1 and B. Formation of hepatic steatosis was associated with HCV genotype 3 virus-induced viral load at ≥ 6 log10 IU/ml and metabolic in VL < 6 log10 IU/ml. In patients with chronic hepatitis C genotype 1, high viral load leads to inhibition of protein synthesis conveyor ApoA1 and increased synthesis of cholesterol, accompanied by abdominal obesity and the formation of insulin resistance. CHC patients with BMI < 25 kg/m2 viral load ≥ 6 log10 ME/ml was associated with dyslipidemia IV type on D. Fredriskson (1970), hyperglycemia, insulin resistance and diabetes. The advanced stage of liver fi brosis (F ≥ 3 on a scale METAVIR) and non-response to treatment were associated with a decrease in HDL cholesterol below normal. With an increase in viral load > 5 log10 ME/ml signifi cantly increased the risk of lipid and carbohydrate metabolism.
APA, Harvard, Vancouver, ISO, and other styles
43

Churbakova, OV V., and DV V. Рechkurov. "MATHEMATICAL MODELLING IN FORECASTING THE EFFICIENCY OF TREATMENT OF CHRONIC HEPATITIS C IN CHILDREN." Science and Innovations in Medicine 2, no. 4 (2017): 53–56. http://dx.doi.org/10.35693/2500-1388-2017-0-4-53-56.

Full text
Abstract:
The study developed a model to predict the response to therapy of children with chronic hepatitis C (CHC) based on a system of multivariate analysis. The mathematical model allows timely correction of treatment, significantly increasing the number of early virologic responses and reducing the probability of recurrence of the disease. Aim -optimization of treatment prior to the onset of therapy with subsequent forecasting of the effectiveness of therapy based on multivariate regression analysis. Materials and methods. The study included 116 patients at the age of 3-18 years with CHC in the replicative phase. Children with CHC were divided into 2 groups of 58 patients. Observations in children with CHC were made using clinical, biochemical, immunological and instrumental methods of research, which helped to obtain the most complete information about children with chronic viral hepatitis C. In the course of the conducted multiple regression analysis, we selected the most significant indicators for the establishment of the resulting mathematical model. Results. The method of forecasting response to therapy in chronic hepatitis C in children, developed on the basis of multivariate regression analysis and mathematical modelling of the most important immunological and biochemical parameters, is clinically efficient and justified.
APA, Harvard, Vancouver, ISO, and other styles
44

S., Prasanth K., and Bindu S. "Sustained viral remission with directly acting antivirals in the treatment of chronic hepatitis C among adolescent (12-17 years) survivors of childhood leukemia." International Journal of Contemporary Pediatrics 8, no. 10 (2021): 1735. http://dx.doi.org/10.18203/2349-3291.ijcp20213739.

Full text
Abstract:
Studies from India highlight the high prevalence of hepatitis C (6-25%) infection in survivors of childhood cancers. Recently Directly acting antivirals (DAA) have been approved for treatment of Chronic hepatitis C (CHC) in children >12 years of age. Even though there are reports of efficacy and safety of DAAs in the treatment of CHC in hematologic disorders like thalassemia, there is minimal data on the efficacy of DAA in the management of chronic hepatitis C among adolescent survivors of childhood leukaemia. We performed this retrospective analysis to study Sustained viral remission (SVR) with DAA in the treatment of CHC among adolescent (12-17 years) survivors of childhood leukemia. This study also aimed to analyze the genotypic profile of hepatitis C virus and adverse effects of the DAA in this group of adolescents (12-17 years). 5 adolescents (12-17 years) who were diagnosed with CHC during August 2017 to May 2020 were enrolled in this observational study. All belonged to genotype 1; received DAA regimen comprising of sofosbuvir 400 mg and ledipasvir 90 mg for 12 weeks with good drug compliance and no major adverse effects. All of them attained SVR at 12 weeks after completing treatment. This study among adolescent survivors of childhood leukaemia with chronic hepatitis C genotype 1, augments data regarding efficacy of a 12 weeks DAA regimen comprising of sofosbuvir 400 mg and ledipasvir 90 mg in the attainment of SVR at 12 weeks after completing treatment.
APA, Harvard, Vancouver, ISO, and other styles
45

Girelli, Domenico, Michela Pasino, Julia Goodnough, et al. "Hepcidin Suppression Relative to Iron Status in Patients with Chronic Hepatitis C." Blood 112, no. 11 (2008): 1860. http://dx.doi.org/10.1182/blood.v112.11.1860.1860.

Full text
Abstract:
Abstract Patients with chronic hepatitis C (CHC) often have increased liver iron deposits, a condition associated with reduced sustained response to antiviral therapy, more rapid progression to cirrhosis, and development of hepatocellular carcinoma. The hepatic hormone hepcidin is a major regulator of iron metabolism that inhibits iron absorption and recycling from erythrophagocytosis. Hepcidin decrease is a possible pathophysiological mechanism of iron overload in CHC, but studies in humans have been hampered so far by the lack of reliable quantitative assays for the 25-amino acid bioactive peptide in serum (s-hepcidin). Using a recently validated immunoassay (Ganz T, Blood 2008, epub Aug 8), we measured s-hepcidin levels in 82 CHC naïve patients and 57 sex-matched healthy controls with rigorous definition of normal iron status. All CHC patients underwent liver biopsy with histological iron score (according to Deugnier YM, Gastroenterology 1992). S-hepcidin was much lower in CHC than in controls (geometric means with 95% CIs: 33.7, 21.5–52.9 versus 90.9, 76.1–108.4 ng/ml, respectively; P<0.001), while both serum ferritin and transferrin saturation were significantly higher in CHC than in controls, as expected. S-hepcidin strongly correlated with serum ferritin in both controls (r=0.741; P<0.001) and CHC patients (r = 0.718; P<0.001). In CHC patients, s-hepcidin also correlated with histological total iron score (r = 0.46; P<0.001), but not with serum interleukin-6 (r = −0.042; P = n.s.). After stratification for serum ferritin quartiles, s-hepcidin levels increased significantly across quartiles in both controls and CHC patients (chi for trend, P<0.001). However, in the latter group s-hepcidin levels were significantly lower than in controls for each corresponding quartile (ANOVA, P<0.001). In the lowest ferritin quartile, s-hepcidin was significantly inversely correlated with viral loading (e.g. serum HCV-RNA IU/ml; r = −0.526; P=0.036), while this association gradually disappeared with increasing ferritin quartiles. These results, together with very recent studies in animal and cellular models (Nishina S, Gastroenterology 2008; Miura K, Hepatology 2008), indicate that though hepcidin regulation by iron stores is maintained in CHC, the suppression of this hormone by HCV is likely an important factor in liver iron accumulation in this condition.
APA, Harvard, Vancouver, ISO, and other styles
46

Derbak, Mariya A., Virа V. Vorobets, Galina M. Koval, et al. "ASSESSMENT OF COLON MICROBIOCENOSIS DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C." Wiadomości Lekarskie 75, no. 10 (2022): 2334–38. http://dx.doi.org/10.36740/wlek202210104.

Full text
Abstract:
The aim: To investigate the peculiarities of colon microbiocenosis disorders in patients with chronic hepatitis C. Materials and methods: 142 patients with CHC were under observation, determination of the degree of liver fibrosis (FibroMax), bacteriological examination of stools and pancreatic elastase was performed. Results: It was found that 59.2% of patients with CHC had gut dysbiosis (DB), of which 61.9% had increased body weight. Intestinal microbiocenosis disorders were manifested by constipation in 57.1% of patients, diarrhea in 31% of patients, and alternating constipation and diarrhea in 11.9% of patients. Bacteriologically, gut dysbiosis was character¬ized by suppression of the growth of normal microflora: Escherichia coli in 47.6%, bifidobacteria in 61.9%, lactobacilli in 53.6%, complete absence of bifidobacteria in 20.2% of cases. In patients with CHC combined with DB deep stages of liver fibrosis (F2-3 and F3-4) are registered 3.6 times more often compared to patients without intestinal dysbiosis (53.6% versus 24.1% and 11.9% versus 3.4%). The degree of gut DB increased in proportion to the stage of liver fibrosis (p<0.05). 32.1% of patients with CHC with dysbiosis were diagnosed with exocrine insufficiency of the pancreas. Conclusions: Gut dysbiosis occurs more often in CHC patients with increased body weight and is characterized by constipation in 59.2% of patients. Intestinal microbiocenosis is characterized by suppression of the growth of normal microflora. In 32.1% of CHC patients with intestinal dysbiosis, according to the results of the pancreatic elastase-1 test, pancreatic exocrine insufficiency of various degrees was found.
APA, Harvard, Vancouver, ISO, and other styles
47

Gaetano, John N., Archita P. Desai, and Nancy Reau. "The Era of Direct-Acting Antivirals: The Evolving Role of Interferon and Ribavirin for the Treatment of chronic Hepatitis C." Clinical Medicine Insights: Therapeutics 4 (January 2012): CMT.S6792. http://dx.doi.org/10.4137/cmt.s6792.

Full text
Abstract:
The burden of disease related to chronic hepatitis C (CHC) continues to increase annually. While our experience with treating CHC began less than 30 years, steady progress has been made in the ability to successfully treat patients, reducing morbidity and mortality. Until recently, the main players in therapy of CHC were interferon and ribavirin. Unfortunately, response to this therapy is successful only in a selected group of patients, leaving a sizeable portion of patients with CHC untreated or with ineffective retreatment options after having failed prior therapy. An in depth understanding of the hepatitis C virus has ushered in the dawn of a new era of therapy for CHC. Two drugs, telaprevir and boceprevir, have recently been approved by the Food and Drug Administration. Many others hold great promise and are in the early phases of drug development. Here, we will review the history of hepatitis C therapy, mechanism of action drugs approved for or in development, current data on clinical safety and efficacy of these agents as well as the role of patient preference in CHC therapy. We will conclude with current recommendations for the treatment of patients with CHC and the evolving role of interferon and ribavirin.
APA, Harvard, Vancouver, ISO, and other styles
48

Kondratovich, I. A., V. M. Tsyrkunov, V. P. Andreev, and R. I. Kravchuk. "CHARACTERISTICS OF HEPATIC STELLATE CELLS PHENOTYPES IN CHRONIC HEPATITIS C." Journal of the Grodno State Medical University 20, no. 4 (2022): 393–99. http://dx.doi.org/10.25298/2221-8785-2022-20-4-393-399.

Full text
Abstract:
Background. Hepatic stellate cells (HSC) play a key role in the development of liver fibrosis in different damages. The aim is to present the structural-functional and quantitative characteristics of various HSC phenotypes in chronic hepatitis C (CHC). Material and methods. The object of the study was 18 liver biopsies of patients with verified CHC (HCV+ RNA in PCR). The stage of liver fibrosis was assessed by Metavir. Structural, functional and quantitative characteristics of different phenotypes of 160 analyzed HSCs at different stages of fibrosis in CHC were assessed by the results of light (semithin sections) and electron microscopy. We determined the average area, length and width of one PSL in each biopsy specimen, the number of lipid droplets in all and in one PSL as well as the average area, length and width of one lipid droplet. Results. At different stages of fibrosis in CHC, all three HSC phenotypes, which had differences in the main structural and quantitative parameters, were simultaneously detected in the patient. Predominantly (44.4%), HSCs corresponding to the non-activated (sleeping) phenotype were detected, less often (20.6%) – those corresponding to the active (myofibroblastic) phenotype. As the HSC was activated, the shape of the cells changed (star-shaped–elongated), the number of lipid droplets in the cell decreased without changing the size of the inclusions, and the cytoplasmic/nuclear ratio changed towards an increase in the nucleus. The frequency distribution of phenotypes depended on the stage of liver fibrosis. Conclusions. Patients with CHC are characterized by the presence of all three HSC phenotypes, which differ from each other in structural and quantitative characteristics, the frequency of which depends on the stage of liver fibrosis.
APA, Harvard, Vancouver, ISO, and other styles
49

Pinsky, L. L., O. A. Golubovska, and M. V. Khaitovich. "STEATOUS CHANGES IN HEPATOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C." Medical Science of Ukraine (MSU) 20, no. 1 (2024): 39–44. http://dx.doi.org/10.32345/2664-4738.1.2024.05.

Full text
Abstract:
Background. The main consequences of progressing of a chronic hepatitis C are a cirrhosis of a liver and hepatocellular carcinoma. Considering that for last years number of cases of CHC disease among population of the world has essentially increased, creation of adequate methods of an estimation of morphological and metabolic shifts in a liver tissue at CHC is the important clinical problem.
 Aim: to determine the morphological features of steatosis in patients with CHC and assess its effect on the progression of hepatitis.
 Materials and methods. Under supervision there were 46 CHC patients in the age of 19 - 66 years, 36 men and 10 - women. Liver biopsy was carried out under the control of ultrasonic research with local anesthesia.
 Conclusion. Among CHC patients steatosis of a liver is observed in 60, 9% of supervised. Expressiveness of steatosis on Hornboll is distributed: 1-st degree at 13,0% of patients, 2-nd – 28,3%, 3-rd – 19,6%, absence of steatosis- at 39,1%. At initial stages of steatosis in hepatocytes of peripheral zone of segments the significant amount lysosomes, which look like lipofuscin granules which contain lipide, electronically-dense, small-sized granular, pigmentary component, safety of structure of organelles, hyperplasia mitochondrions. At expressed steatosis dense lipid vacuoles which borrow the most part of cytoplasm of hepatocytes, displace organelles, deform a kernel of cells, damage superficial membranes mitochondrions are observed. In periportal zone, on border of contact of hepatocytes which contain lipid granules, and lymphomonocytic infiltrate, the expressed activation of Kupfer cells, insufficiency of granules in cells of ITO, their transformation in fibroblasts, the expressed adjournment of collagenic fibers is observed.
APA, Harvard, Vancouver, ISO, and other styles
50

Kaviani, R., F. Y. Chou, C. B. He, and V. Marquez. "A95 ASSESSMENT OF BIRTH COHORT SCREENING OF CHRONIC HEPATITIS C IN COLORECTAL CANCER SCREENING PATIENTS IN BRITISH COLUMBIA." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (2023): 51–52. http://dx.doi.org/10.1093/jcag/gwac036.095.

Full text
Abstract:
Abstract Background Birth cohort screening of chronic hepatitis C (CHC) is recommended in British Columbia since 2018 for baby boomers born between 1945 to 1964, with an estimated provincial prevalence of 2.31%. Though there remained a gap in care following anti-hepatitis C positivity, resulting in reflexive ribonucleic acid (RNA) testing provincially. Dual screening of CHC in patients referred to colorectal (CRC) screening programs can provide an opportunity to link patients with healthcare professionals to ensure appropriate follow-up. Purpose We aimed to assess the uptake of CHC screening amongst CRC screening patients after the release of British Columbia’s birth cohort guidelines, both pre and post-COVID-19 pandemic. Method A retrospective review of patients referred to a CRC screening program in Vancouver from October 1st to December 31st, 2019, and December 1st – 31st, 2021, was performed. Collected data included demographics, liver disease history, and co-infection rates with hepatitis B (HBV) or human immunodeficiency virus (HIV). Dates of first-time hepatitis C antibody, RNA and viral load testing were gathered. Descriptive statistics were used to identify the proportion of screening and prevalence of CHC. Result(s) A total of 553 patients were referred for colonoscopy to the CRC screening program, of whom 458 (82.8%) patients were born between 1945 to 1964, and 273 (n=49%) were female. Among the 250 (45.2%) patients screened for CHC, 4 (0.72%) had positive anti-hepatitis C, all of whom were baby boomers. In 2019, 44% (n=183) of patients were screened for CHC; 78.7% (n=144) were screened before colonoscopy referral. In 2020, 48.6% (n=67) of patients were screened for CHC; 100% of cases were screened before colonoscopy referral. Conclusion(s) Birth cohort screening of CHC is underutilized in British Columbia. Dual screening of CHC at the time of referral to CRC screening provides a practical approach to linking patients to healthcare. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography